The cost effectiveness of mycophenolate mofetil in the first year after primary cadaveric transplant

Journal of the American Society of Nephrology

Volumn 8, Issue 10, 1997, Pages 1592-1598

  Sullivan, Sean D ^a   Garrison, Louis P ^b   Best, Jennie H ^b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b ROCHE BIOSCIENCE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; GRAFT REJECTION; HUMAN; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0030659650     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: 10.1681/asn.v8101592     Document Type: Article

References (19)

1. U.S. Department of Health and Human Services: End Stage Renal Disease Research Report 1993-1995, Baltimore, MD, Health Care Financing Administration, 1997, in press
2. Eggers PW: Analyzing the cost-effectiveness of kidney transplantation. Presented at the 19th National Meeting of Public Health Conference on Records and Statistics (Department of Health and Human Services Publication No. [PHS] 84-1214), 1984
3. Tousignant P, Guttman RD, Hollomby DJ: Transplantation and home hemodialysis: Their cost-effectiveness. J Chronic Dis 38: 589-601, 1985
4. Krakauer H: Assessment of alternative technologies for the treatment of end-stage renal disease. Isr J Med Sci 22: 245-259, 1986
5. Eggers PW: Comparison of treatment costs between dialysis and transplantation. Semin Nephrol 12: 284-292, 1992
6. Simon DG: A cost-effectiveness analysis of cyclosporine in cadaveric kidney transplantation. Med Decis Making 6: 199, 1986
7. Showstack J, Katz P, Amend W, Salvatierra O: The association of cyclosporine with the 1-year costs of cadaver-donor kidney transplants. JAMA 264: 1818-1823, 1990
8. Evans RW, Manninen DL: Economic impact of cyclosporine in transplantation. Transplant Proc 20[Suppl 3]: 49-62, 1988
9. Sollinger HW, for the U.S. Renal Transplant Mycophenolate Mofetil Study Group: Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. Transplantation 60: 225-232, 1995
10. American Hospital Association: American Hospital Association Hospital Statistics, Chicago, American Hospital Association, 1994
11. Koyama H, Cecka JM: Rejection episodes. In: Clinical Transplantation 1992, edited by Terasaki PI, Cecka JM, Los Angeles, UCLA Tissue Typing Laboratory, 1993, pp 391-404
12. Keown P, for the Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group: A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation 61: 1029-1037, 1995
13. European Mycophenolate Mofetil Cooperative Study Group: Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. Lancet 345: 1321, 1995
14. Drummond MF, Davies L: Economic analysis alongside clinical trials. Intl J Med Technol Assess Health Care 7: 561, 1991
15. Sheldon T: Problems of using modeling in the economic evaluation of health care. Health Econ 5: 1, 1996
16. Almond PS, Matas A, Gillingham K: Risk factors for chronic rejection in renal allograft recipients. Transplantation 55: 752, 1993
17. Ferguson R: Acute rejection episodes: Best predictor of long-term primary cadaveric renal transplant survival. Clin Transplant 8: 328, 1994
18. Matas AJ, Gillingham KJ, Payne WD, Najarian JS: The impact of an acute rejection episode on long-term renal allograft survival. Transplantation 57: 857, 1994
19. Sollinger HW: Mycophenolate mofetil. Kidney Int 48[Suppl]: S14, 1995